Qian Li, Yuan Fang, De-Wei Peng, Lu-An Li, Chun-Yu Deng, Hui Yang, Su-Juan Kuang, Qiao-Qiao Li, Meng-Zhen Zhang, Peng Zeng, Qian-Huan Zhang, Yang Liu, Hai Deng, Wei Wei, Yu-Mei Xue, Shu-Lin Wu, Fang Rao
AIM: Sacubitril/valsartan (Sac/Val, LCZ696), the world's first angiotensin receptor-neprilysin inhibitor (ARNi), has been widely used in the treatment of heart failure. However, the use of Sac/Val in the treatment of atrial fibrillation (AF), especially AF with hypertension, has been less reported. We investigated the effect of Sac/Val on atrial remodeling and hypertension-related AF. METHODS: The AF induction rate and electrophysiological characteristics of spontaneously hypertensive rats (SHRs) treated with Sac/Val or Val were detected by rapid atrial pacing and electrical mapping/optical mapping...
May 12, 2023: European Journal of Pharmacology